Announced
Completed
Financials
Sources
Tags
Acquisition
Minority
Single Bidder
biotechnology company
United States
Biotechnology
Domestic
Private
Private Equity
Completed
Friendly
Venture Capital
Synopsis
Foresite Capital, an American venture capital and growth equity firm, Samsara BioCapital, an investment company and venBio Partners, a life sciences investment firm, led a $259m Series C round in Alumis, a clinical-stage biopharmaceutical company. "We are pleased to announce our successful Series C financing and we are grateful for the support of our strong investor syndicate, a group that shares our commitment to transforming the treatment paradigm for patients living with immune-mediated diseases. This investment will support the continued clinical development of ESK-001, building on promising data that have demonstrated full, sustained target inhibition leading to a potentially best-in-class oral TYK2 inhibitor profile,” Martin Babler, Alumis President and CEO.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.